Relative Bioavailability of Pimasertib in Cancer Patients
Status:
Completed
Trial end date:
2015-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over
trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in
cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial
extension phase).